AVANCE CON SU PROGRAMA DE NEFROLOGÍA CON UN SOCIO CON EXPERIENCIA

Nefrología

Contáctenos

Trabaje con líderes en investigación clínica en nefrología

Optimice su desarrollo clínico con experiencia operativa

Aproveche los datos exclusivos para fundamentar las decisiones sobre el diseño de su estudio

Connect with our nephrology experts 

Barbara S. Gillespie, MD, MMS, FASN

Barbara S. Gillespie, MD, MMS, FASN
Vicepresidenta y Directora Terapéutica del Departamento de Nefrología de Labcorp Drug Development
Profesora Adjunta del Departamento de Nefrología e Hipertensión de la Facultad de Medicina de la Universidad de Carolina del Norte

Dr. Gillespie, board-certified in nephrology, joined Labcorp in 2017 after over a decade of leadership experience at Quintiles, where she held a variety of positions. These duties included reporting directly to the Chief Medical and Scientific Officer and serving as Global Therapeutic Lead for Nephrology and North American Head of the U.S. Internal Medicine team.

Dr. Gillespie serves on the board of directors of the Kidney Health Initiative (a public-private partnership between the FDA and the American Society of Nephrology) as well as on the steering committee for the National Kidney Foundation (NKF) Chronic Kidney Disease Registry. She is also on the board of directors for Nephronet and the Cardio Renal Society of America, has served on several global work groups and advisory boards for academic and trial-related stakeholders (including NKF, NephCure, Kidney Disease Improving Global Outcomes, ISN, Patient-Centered Outcomes Research Institute/University of North Carolina and PREPARE-NS) and has presented in many global forums and renal conferences.

She is also a past associate medical director at a small local dialysis unit and a fellow of the American Society of Nephrology. Dr. Gillespie received board certification in internal medicine in 2004 and in nephrology in 2006 and 2015. She completed her internal medicine residency at University of North Carolina and her nephrology fellowship at Duke.


Jennifer Ennis, MD

Jennifer Ennis, MD
Directora Médica, Soluciones Clínicas y Digitales de Labcorp Diagnostics

Dr. Ennis, board-certified in internal medicine and nephrology, joined Labcorp Diagnostics as a medical director in 2009. In this role, she led the development of Labcorp's suite of laboratory-based clinical decision support offerings, including chronic kidney disease, cardiovascular disease and diabetes. En 2020, se convirtió en Directora Médica de Soluciones Clínicas y Digitales, donde se encarga de la dirección clínica y la supervisión de la cartera de soluciones tecnológicas orientadas al cliente de Labcorp y lidera un equipo de médicos en la creación de contenidos para la cartera. She provides subject-matter expertise for nephrology initiatives throughout the organization and serves as a Labcorp representative on the National Kidney Foundation Laboratory Engagement Committee.

Dr. Ennis is also a clinical associate professor of medicine in the section of nephrology at the University of Illinois at Chicago where she sees patients weekly, lectures and supervises medical trainees. Además de estas responsabilidades, realiza investigaciones clínicas sobre la enfermedad renal crónica y es autora de varios resúmenes y publicaciones revisadas por pares.

Dr. Ennis earned her MD from the University of Pittsburgh School of Medicine and completed internal medicine residency and nephrology fellowship training at the University of Chicago Medical Center. Es miembro del American College of Physicians.


Katherine T. Landschulz, PhD

Katherine T. Landschulz, PhD

Directora Sénior y Líder del Área Terapéutica de Enfermedades Cardiovasculares, Metabólicas, Renales y Neurodegenerativas, Centro de Soluciones de Biomarcadores de Labcorp

Dr. Landschulz joined Labcorp Drug Development in 2010, after more than a decade as a scientist in discovery through translational medicine roles at Pfizer, Abbott and Eli Lilly. At Labcorp, Dr. Landschulz helped establish the exploratory biomarker laboratory, Translational Biomarker Solutions, and served as associate director of this team prior to joining the newly established Biomarker Solution Center in 2018.

As Renal Disease Therapeutic Area Lead for the Labcorp Biomarker Solution Center, Dr. Landschulz is responsible for the delivery of biomarker strategies for sponsor programs in renal disease indications (e.g., acute kidney injury, chronic/diabetic kidney disease). Dr. Landschulz serves as a consultant to sponsors and teams, advising on matters related to biomarker selection and strategy development, laboratory placement of testing, feasibility designs and overall guidance around translational and exploratory biomarker data in drug development. La Dra. Landschulz también se desempeña como intermediaria; en esta función, dirige las preguntas y conecta a los científicos de biomarcadores del patrocinador y de Labcorp. Finally, Dr. Landschulz participates in enterprise-wide assessments and the licensing and implementation of new laboratory biomarker and tests transitioning from clinical trial to clinical care utilization.

Dr. Landschulz received her BSc in genetics at the University of California, Davis and her PhD in genetics/biology from Johns Hopkins University. Completó sus estudios posdoctorales en Johns Hopkins y en University of Texas, Southwestern Medical School, antes de incorporarse a la industria biofarmacéutica en 1997.


Somos su fuente de confianza para llevar a cabo estudios renales, desde el apoyo para estudios por primera vez en humanos en nuestras unidades de fase I hasta el diseño, la planificación, la gestión y la puesta en marcha de estudios globales de fase II a IV. Nuestra experiencia médica y operativa abarca una amplia gama de indicaciones nefrológicas que incluyen, entre otras, las siguientes áreas:

  • Acute kidney injury
  • Diabetic kidney disease
  • Chronic kidney disease and associated complications (e.g., hyperkalemia and hyperphosphatemia)
  • Glomerular disease including focal segmental glomerulosclerosis, IgA nephropathy and lupus nephritis
  • End-stage kidney disease: dialysis (and associated complications such as cardiovascular outcomes) and kidney transplant
  • Rare renal diseases
  • Renal devices
  • Renal impairment
  • Renal cell carcinoma


Develop new perspectives through proprietary data

Dar prioridad al recorrido del paciente y a los datos asociados es fundamental para el éxito de los ensayos. En Labcorp, podemos crear y aplicar una estrategia aplicable a la indicación específica y a la población de pacientes de su estudio. Starting with vast patient diagnostic data from Labcorp's database of longitudinal patient data and site-specific recruitment metrics from our Central Laboratory and clinical investigator database, we can:

  • Design the most efficient trial by focusing on the highest enrolling countries and sites and eliminating nonperformers
  • Identify patients meeting your inclusion criteria who are near clinical trial sites and connect them to your trial
  •  Fully inform your protocol design to maximize recruitment and save time and money

Comprehensive, multifunctional nephrology experience and expertise to deliver better outcomes

Whether your study is looking for a rare population, expecting aggressive enrollment timelines or operating in a highly competitive environment, Labcorp has the expertise, data and experience to support trial design, proactively mitigate risk and deliver results. 

Conversemos

Contáctenos